Consensus estimates from Visible Alpha project second-quarter revenue of $15.42 billion, up from $14.46 billion in the same period last year, with core earnings per share expected to reach $2.48. Despite these figures, market sentiment remains fragile following a 4% dip in share price during the second quarter. The decline accelerated in July after the company reported that its drug Wainua failed to reduce mortality rates in a critical heart condition trial.

Attention now shifts to the company's R&D pipeline. Analysts at Jefferies are closely monitoring upcoming data on a combination therapy of Datroway and Imfinzi for lung cancer, viewing it as a significant potential revenue driver. Meanwhile, updates on Etcamah breast cancer trials face heightened skepticism following a similar setback for Roche earlier this year. While Bernstein analysts maintain that AstraZeneca holds the industry's deepest pipeline, the Wainua miss has prompted questions regarding the feasibility of the company's ambitious $80 billion revenue target for 2030. UBS analysts currently maintain that the goal remains achievable, though they see little room for the company to upgrade its 2026 financial guidance.